Biomarkers of response to cabozantinib in patients with neuroendocrine tumors

Year: 2018
Institution: Dana-Farber Cancer Institute
Country: United States
State: MA
Award Type: NETRF GRANTS 2005-2017
NET Type: Multiple
Science Type: Clinical

General Description

This one-year Pilot Project will evaluate data and patient samples from a phase II clinical trial of cabozantinib, a targeted therapy that showed promise in treating NETs. Cabozantinib has been shown to induce cancer cell death in other types of cancers. In this study, Chan and colleagues will analyze samples from their clinical trial to look for biomarkers that could predict response to cabozantinib. Their findings will be applied to a future investigation in a phase III clinical trial of cabozantinib in NET planned by Chan and colleagues.


Read more about this study